ANTX AN2 Therapeutics, Inc.
$5.41▼ -4.92%
Healthcare
Other
After hours
$5.41▲ +0.00%
Sep 11, 7:30 PM ET
Volume 103.5K
Avg Volume (10D) 214.5K
Key Metrics & Fundamentals
Market Cap
$204.15M
P/E Ratio
–
Div Yield
–%
52W Range
1.00 - 7.19
% vs 50 MA
0.82%
% vs 200 MA
55.77%
RSI-14
43.7
MACD Histogram
-0.0500
Beta (1Y vs SPY)
0.62
Free Cash Flow
-$7.00M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$8.90M
COGS
–
Operating Exp
$8.90M
Operating Income
-$8.90M
EBIT
-$8.90M
Pretax Income
-$8.19M
Net Income
-$8.19M
EPS (Diluted)
-0.18
Price & Volume History
Loading chart…
Recent News
AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
Business Wire · Aug 31, 2026 10:00 PM
Nontuberculous Mycobacterial Infections Market to Showcase Growth at a CAGR of 12.6% During the Forecast Period (2026–2036), Driven by Rising Disease Burden and Emerging Therapies | DelveInsight
GlobeNewswire · Aug 31, 2026 5:00 PM
AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer
Business Wire · Aug 24, 2026 11:00 AM
AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights
Business Wire · Aug 11, 2026 8:00 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See ANTX's money flow as a full page
Social Sentiment
Avg -0.80 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.